Standard BioTools
LAB
79 hedge funds and large institutions have $291M invested in Standard BioTools in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 34 increasing their positions, 23 reducing their positions, and 11 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 23
35% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $1.04M
28% more capital invested
Capital invested by funds: $227M → $291M (+$64.3M)
1.46% more ownership
Funds ownership: 97.77% → 99.23% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 84 → 79 (-5)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$3.19M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$1.6M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$891K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$866K |
| 5 |
Renaissance Technologies
New York
|
+$585K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.6M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$863K |
| 3 |
Jennison Associates
New York
|
-$410K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$339K |
| 5 |
BlackRock
New York
|
-$276K |
LAB Hedge Fund Activity: Q3 2018 in Review
79 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2018, worth a combined $291M — up 28% from $227M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LAB and 6 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 34 added.
The largest buyer was Endurant Capital Management, adding an estimated $3.19M. The largest seller was OrbiMed, cutting an estimated $3.6M.
- 79 institutional investors held Standard BioTools (LAB) as of Q3 2018, down from 84 in Q2 2018.
- Funds reported $291M of Standard BioTools stock for Q3 2018, up 28% quarter-over-quarter.
- 6 funds opened new Standard BioTools positions in Q3 2018 and 11 closed out, a net change of -5 holders.
- The largest Standard BioTools buyer in Q3 2018 was Endurant Capital Management, an estimated $3.19M added.
- The largest Standard BioTools seller in Q3 2018 was OrbiMed, an estimated $3.6M sold.
Based on aggregated 13F filings for Q3 2018.